We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Josh Beckerman
Entasis Therapeutics Holdings Inc., a developer of antibiotics that spun out from AstraZeneca PLC (AZN, AZN.LN) in 2015, has revealed its plans for an initial public offering.
Entasis, which previously filed confidential IPO paperwork, said in its Form S-1 Friday it has applied to list on Nasdaq under symbol ETTX.
The Waltham, Mass., biopharmaceutical company filed to offer up to $86.25 million, but that is a placeholder amount likely to change.
AstraZeneca owns a 21.6% stake in Entasis. Other large shareholders include Clarus Ventures, which owns 14.7%.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 17, 2018 20:03 ET (00:03 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
